Entrectinib’s mechanism of action

Entrectinib (Entrectinib) is a targeted therapy drug mainly used to treat cancers carrying ALK (tyrosine kinase) and ROS1 (tyrosine kinase) fusion mutations. Its mechanism of action involves the following aspects:

1.Inhibit abnormally activated ALK and ROS1 fusion protein:

In some tumors, ALK and ROS1 genes may undergo fusion mutations, resulting in the production of abnormally activated ALK and ROS1 fusion proteins. These abnormally activated fusion proteins promote the proliferation, growth and spread of tumor cells. As a targeted therapy drug, entrectinib can specifically bind and inhibit these abnormally activated fusion proteins, blocking their signaling pathways, thereby inhibiting the proliferation and growth of tumor cells.

2.Interfering with the signaling pathways of tumor cells:

In addition to directly inhibiting the ALK and ROS1 fusion proteins, entrectinib may also affect other signaling pathways related to these fusion proteins. These pathways may be involved in key processes such as cell proliferation, survival, and apoptosis. By interfering with these signaling pathways, entrectinib further blocks the tumor cells' ability to grow and survive.

3.Inhibit tumor angiogenesis:

Some studies have shown that entrectinib may also inhibit tumor angiogenesis. Tumor angiogenesis is critical for tumor growth and metastasis, and the inhibitory effect of entrectinib may help block the tumor's blood supply, thereby limiting tumor growth and spread.

To sum up, entrectinib, as a targeted therapy drug, inhibits the proliferation, growth and spread of tumor cells by inhibiting abnormally activated ALK and ROS1 fusion proteins and interfering with related signaling pathways. In addition, it may also inhibit tumor angiogenesis, providing another important mechanism for tumor treatment.